#47988

ក្តី ក្តី TNFRSF17/BCMA Antibody



Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 18, 23	Source/Isotype: Rabbit	UniProt ID: #Q02223	Entrez-Gene Id: 608	
Product Usage Information		Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:50		
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.					
Specificity/Sensitivity TNFRSF17/BCMA Antibody recognizes endogenous lev				dogenous levels of total	TNFRSF17/BCMA p	rotein.	
Source / Purifi	cation	Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu115 of human TNFRSF17/BCMA protein. Antibodies are purified by protein A and peptide affinity chromatography.					
Background		B cell maturation antigen (BCMA/TNFRSF17/CD269) is a transmembrane glycoprotein and member of the TNFR superfamily (1). BCMA expression is largely restricted to the B cell lineage. Pro-survival signaling through this receptor plays a pivotal role in humoral immunity by regulating B cell maturation and plasma cell differentiation upon binding its ligands, BAFF and APRIL (2-6). BCMA is expressed in a number of B cell malignancies and has garnered much attention as a novel therapeutic target for the treatment of multiple myeloma due to its selective and elevated expression on the cell surface of malignant plasma cells (7-10).					
Background Ro	eferences	 Madry, C. et al. (1998) Int Immunol 10, 1693-702. Chiu, A. et al. (2007) Blood 109, 729-39. Avery, D.T. et al. (2003) J Clin Invest 112, 286-97. O'Connor, B.P. et al. (2004) J Exp Med 199, 91-8. Darce, J.R. et al. (2007) J Immunol 178, 5612-22. Xu, S. and Lam, K.P. (2001) Mol Cell Biol 21, 4067-74. Carpenter, R.O. et al. (2013) Clin Cancer Res 19, 2048-60. Tai, Y.T. et al. (2004) Blood 103, 3148-57. Tai, Y.T. et al. (2014) Blood 123, 3128-38. 					
Species Reactiv	vity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).					
Western Blot E	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.					
Applications K	ey	W: Western Blotting IP: Immunoprecipitation					
Cross-Reactivit	ty Key	H: Human					
Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.							
		All other trademarks a more information.	re the property of	their respective owners.	Visit cellsignal.com	/trademarks for	
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.					

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.